Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422692 · ClinicalTrials.gov registry record · Phase 1
Socket Preservation: A Clinical and Histological Study
A Phase 1 study, sponsored by University of Kentucky.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03422692 is a Phase 1 study that has completed, run by University of Kentucky. The registered enrollment target is 43 participants.
The verdict
NCT03422692, a Phase 1 study, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the use of human amnion chorion membrane (BioXclude®) as an exposed barrier in ridge preservation and whether the intentional exposure of this membrane to oral environment will adversely affect ridge healing, dimensions, and bone vitality. This is a randomized clinical study.
Interventions
- BIOLOGICAL BioXclude amnion-chorion membrane
- BIOLOGICAL Mem-Lok collagenous membrane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-10-01 |
| Est. Completion | 2015-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03422692
The ClinicalTrials.gov registry entry for NCT03422692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kentucky, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BioXclude amnion-chorion membrane is the first listed.
NCT03422692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03422692 about?
NCT03422692 is a clinical study titled "Socket Preservation: A Clinical and Histological Study". The objective of this study is to investigate the use of human amnion chorion membrane (BioXclude®) as an exposed barrier in ridge preservation and whether the intentional exposure of this membrane to oral environment will adversely affect ridge healing, dimensions, and bone vitality. This is a rand...
What is the current status of trial NCT03422692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2013-10-01. Estimated completion is 2015-10-01.
What interventions are being tested in trial NCT03422692?
The interventions under investigation include: BioXclude amnion-chorion membrane (BIOLOGICAL), Mem-Lok collagenous membrane (BIOLOGICAL).
Who is sponsoring clinical trial NCT03422692?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.